SEP-479 SAD/MAD data in Q1 2027 is the next major binary catalyst. The SEP-631 strategic pivot from a Phase 2b CSU study to signal-finding studies suggests a more cautious, capital-efficient approach, watch for clarity on study design and indications. The Novo Nordisk collaboration provides a steady revenue stream, but the stock remains a pipeline story. Cash runway into 2029 removes near-term financing risk.
Drugs in focus
SEPN drug pipeline →SEP-479
● Neutral Named in this 8-K- Impact
- Phase
- Phase 1
- Time to market
- If Phase 1 data are positive, SEP-479 would still need to complete Phase 2 and Phase 3 trials before any potential FDA submission, placing a potential approval several years away (likely 2029-2031 at the earliest).
- Next catalyst
- None dated
What to watchThe next catalyst for SEP-479 is the Phase 1 topline safety, PK and PD data readout, guided for late 2026 or early 2027. Positive data would validate the oral small-molecule approach against an injectable standard of care (YORVIPATH) and could drive SEPN shares higher given the strong analyst consensus. Negative data (safety signals or poor PK/PD) would be a significant setback for Septerna's lead wholly-owned program.
Price Chart
Executive Summary
Septerna reported Q2 2026 financial results with a net loss of $13.0M, narrower than the $24.8M loss in Q2 2025. Revenue from the Novo Nordisk collaboration was $26.7M, and the company ended the quarter with $516.5M in cash, sufficient to fund operations into 2029. Key pipeline updates include the ongoing Phase 1 trial for SEP-479 (PTH1R agonist) with SAD/MAD data expected in Q1 2027, and a strategic shift for SEP-631 away from a Phase 2b CSU study toward capital-efficient signal-finding studies in mast cell-driven diseases.
Key Financial Metrics
Key Facts
- Net loss of $13.0M for Q2 2026 vs $24.8M for Q2 2025; revenue of $26.7M from Novo Nordisk collaboration vs $0.1M from Vertex in Q2 2025.
- Cash position of $516.5M as of June 30, 2026, expected to fund operations at least into 2029.
- Phase 1 trial for SEP-479 (PTH1R agonist) ongoing; elimination half-life ~3-4 days supports once-daily dosing; SAD/MAD data expected Q1 2027.
- SEP-631 strategic shift: company evaluating capital-efficient signal-finding studies in mast cell-driven diseases instead of the previously planned Phase 2b in CSU.
- TSHR NAM program progressing toward development candidate selection; Novo Nordisk collaboration advancing.
Financial Impact
No material financial impact; Q2 net loss $13.0M, revenue $26.7M, cash burn rate consistent with prior quarter.
Risk Factors
- SEP-479 Phase 1 data delay or negative safety/efficacy findings in Q1 2027.
- SEP-631 development uncertainty due to strategic reprioritization away from Phase 2b CSU.
- High R&D spend ($35.1M in Q2) may accelerate cash burn if pipeline timelines slip.
- Early-stage pipeline, no approved products; all value tied to clinical execution.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-342328 |
| Document: sepn-20260810.htm | 0001193125-26-342328 |
| Document: 0001193125-26-342328-index-headers.html | 0001193125-26-342328 |
| Document: 0001193125-26-342328-index.html | 0001193125-26-342328 |
| Document: 0001193125-26-342328.txt | 0001193125-26-342328 |
| 8-K Data (Synthetic) | 0001193125-26-342328 |
Track record
25 reports on SEPN
7 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +55.96% at T+60 after the Apr 13, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry price pending
- Nov 16, 2026today 144 Neutral 2/10 Entry price pending
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $42.60 Now $42.60 −0.00% settles Nov 20
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $42.60 Now $42.60 −0.00% settles Nov 20
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $41.86 Now $42.60 +1.77% settles Nov 19
- Nov 9, 20267d ago Press Release Bearish 5/10 Entry $52.34 Now $42.60 +18.61% settles Nov 17
- Nov 4, 202612d ago 8-K Neutral 3/10 Entry $47.88 to $48.56 Now $42.60 −11.03% ▲ +1.42% +2.33% vs SPY
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $47.88 to $48.56 Now $42.60 −11.03% ▲ +1.42% +2.33% vs SPY
- Sep 10, 20269w ago Press Release Neutral 2/10 Entry $38.51 to $38.69 Now $42.60 +10.62% ▲ +0.47% +0.69% vs SPY
- Sep 3, 202610w ago 3 Neutral 2/10 Entry $36.75 to $39.55 Now $42.60 +15.92% ▲ +7.62% +8.83% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers